Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
Launched by ZHEJIANG CANCER HOSPITAL · Jul 6, 2025
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool called the GRAPE model to help find stomach (gastric) cancer earlier and more accurately. The goal is to see how well this model works at detecting stomach cancer at different stages, which could help doctors screen patients more effectively.
People who are between 18 and 80 years old and are already having a CT scan of their chest and abdomen may be eligible to join. Participants need to agree to take part and sign a consent form. However, people who have already been diagnosed with stomach cancer or have serious difficulties with communication or understanding are not eligible. If you join, you can expect to have your CT scan results reviewed using the GRAPE model to see if it helps identify any signs of stomach cancer. This study is currently recruiting participants and welcomes adults of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged between 18 and 80 years
- • Individuals undergoing thoracoabdominal CT examination
- • Voluntarily participated in the study and provided written informed consent
- Exclusion Criteria:
- • Patients with confirmed diagnosis of gastric cancer
- • Individuals with severe intellectual disabilities or communication disorders
About Zhejiang Cancer Hospital
Zhejiang Cancer Hospital is a leading medical institution in China, dedicated to advancing cancer research, treatment, and patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices to improve outcomes for cancer patients. With a multidisciplinary team of experienced oncologists and researchers, Zhejiang Cancer Hospital is committed to fostering collaboration and leveraging cutting-edge technology in its clinical trials. The institution aims to contribute significantly to the global understanding of cancer and enhance therapeutic options through rigorous research and development initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Xiangdong Cheng
Principal Investigator
Zhejiang Cancer Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported